The Urinary Tract Infection Therapeutics Market is expected to register a CAGR of 4.1% during the forecast period. Certain factors that are driving the market growth include the increasing prevalence of diabetes and kidney stones and the launch of combination drugs.
Key Highlights According to a study published in Advances in Urology 2018, Kidney stone disease is an increasing urological disorder of human health which is affecting about 15% of the world population and it affects all age groups but occurs more frequently in men than in women within the age of 20–49 years. Moreover, during a lifetime, approximately 7% of women and 13% of men will develop a kidney stone.
Therefore, with the increasing prevalence of diabetes and kidney stones, the number of cases of urinary tract infection (UTI) increases, which in turn, increases the demand for drugs, thus, driving the global urinary tract infection therapeutics market.
Additionally, the launch of more efficient combination drugs and increasing geriatric population are expected to boost the growth of the urinary tract infection therapeutics market.
However, according to the Center for Education & Research on Therapeutics, over 2 million cases of adverse drug reactions (ADRs) are reported every year, leading to approximately 100,000 deaths.
According to the FDA, it is estimated that, in the United States, each year, over 350,000 ADRs occur in nursing homes alone.
With an increase in the number of cases of ADRs being reported, globally, there is an awareness among the population about the adoption of drugs, which is acting as a major restraint for the urinary tract infection therapeutics market.
Additionally, the lack of awareness about the prevalence of UTIs in the developing and underdeveloped countries is also restraining the growth of the market.
Key Market Trends
Complicated UTIs Segment is Expected to Hold a Major Market Share in the Urinary Tract Infection Therapeutics Market
The prevalence of complicated UTI is expected to increase in the future, owing to the rise in drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe quinolones to treat complicated UTI cases. Cephalosporin is the second-most common drug prescribed for complicated UTI cases.
According to the American Academy of Family Physicians (AAFP), kidney stones are a common disorder, with an annual incidence of eight cases per 1,000 adults. Moreover, around 13% of men and 7% of women develop a kidney stone in their lifetime and the overall incidence of urinary retention is 4.5 to 6.8 per 1,000 men, per year, in the United States. Overall, the prevalence of complicated UTI is set to increase during the forecast period, mainly owing to the increasing bacterial resistance in UTI cases and rise in recurrence rate for UTI.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The region is experiencing a drastic increase in innovations related to diagnostic methodologies used for UTIs. In recent events, during a routine checkup for UTI, a woman was observed to be infected by E. coli that showed resistance to the last-resort antibiotic, Colistin. The discovery of Colistin-resistant bacteria was considered a major issue. In addition to that, the CDC, in collaboration with other organizations, developed guidelines for the prevention of catheter-associated UTIs and other types of healthcare-associated infections in the United States.
Furthermore, According to the Queensland Pediatric Factsheet 2019, estimates that approximately 1 in 10 girls and 1 in 50 boys will suffer from a urinary tract infection by seven years of age. Infections in children under one year are more common in boys but in older children infections are more common in girls. Thus, owing to the above factors the market is expected to show growth in the coming years.
The urinary tract infection therapeutics market is fragmented competitive and consists of a number of major players. Some of the companies which are currently dominating the market are AstraZeneca, Bayer AG, Cipla Inc., GlaxoSmithKline PLC, Shionogi & Co., Ltd, Novartis AG, and Pfizer, and others.
The market estimate (ME) sheet in Excel format
3 months of analyst support
Our reports have been used by over 10K customers, including:
The frozen tissues samples market is projected to reach US$ 105,045.91 Thousand by 2028 from US$ 44,399.07 Thousand in 2021; it is estimated to grow at a CAGR of 13.1% during 2021-2028. The report highlights trends prevailing in the market and the factors driving it.The growth of the frozen tissues samples market is attributed to the...
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 18.104.22.168) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 22.214.171.124) - Janus kinase 2 is a non-receptor tyrosine...
The anatomic pathology market is projected to reach US$ 33,145.78 million by 2028 from US$ 21,488. 41 million in 2021; it is estimated to grow at a CAGR of 6.4% from 2021 to 2028. Factors such as increase in the prevalence of cancer and other diseases, and growing focus on personalized medicines. However, the lack of skilled professionals...
The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on...
269 pages •
By The Business Research Company
• Aug 2021
Anatomic Pathology Equipment and Consumables Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists, marketers and senior management with the critical information they need to assess the global anatomic pathology equipment and consumables market as it emerges from the COVID 19 shut down. Description: Where...
The human microbiome market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021-2028. The market growth is mainly attributed to factors such as the increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, and growing...
Best foot forward: Revenue will likely rise as more healthcare providers stress the importance of preventive care Abstract Podiatrists in the US Over the five years to 2019, the Podiatrists industry has stepped in the right direction. Revenue growth has been supported by the aging US population and...
Respiratory Syncytial Virus Prophylaxis - Global Drug Forecast and Market Analysis to 2030 Summary Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae.The most common clinical scenario for RSV is an...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
Melanoma - Epidemiology Forecast to 2029 Summary Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017).Melanocytes are embryological derivatives of neural crest tissue, and...
Health Provider Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.